Clinical TrialApr 13, 2026, 07:51 AM
Allogene's ALPHA3 Trial Shows 41.6% MRD Clearance Difference
AI Summary
Allogene Therapeutics announced positive interim futility analysis results from its pivotal Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. The analysis showed 58.3% of patients in the cema-cel arm achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, representing a 41.6% absolute difference. This significant difference in MRD clearance is expected to translate into meaningful clinical benefit, indicating a promising outlook for the trial.
Key Highlights
- Cema-cel arm achieved 58.3% MRD negativity.
- Observation arm achieved 16.7% MRD negativity.
- 41.6% absolute difference in MRD clearance.
- Analysis based on first 24 randomized patients.
- Difference exceeds 25-30% for meaningful benefit.